Company profile
IGC Pharma, Inc.
AMEX: IGC · Healthcare · Biotechnology
#880 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
45DFH 40DQ 57GM 30SS 62
v0.1 · 65/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$1.2M
Rev growth YoY (TTM)
-6.7%
Net income (FY)
-$4.1M
Employees
70
as of 2026-08-20
Market cap
$28.6M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$869.0k$869.0k2025
Net income-$4.1M-$4.1M2025
Operating income-$7.7M-$7.7M2025
Total assets$9.7M$9.7M2025
Liabilities$2.3M$2.3M2025
Equity$7.4M$7.4M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Tolling White Labeling Service Member100%
By geography
UNITED STATES100%
COLOMBIA0%
The read
What is IGC Pharma, Inc.’s revenue?
IGC Pharma, Inc. booked $869.0k in FY2025 revenue, contracting 32% year over year — slower than 76% of Healthcare companies we track, at a -477.1% net margin.
Peers · Healthcare
ProKidney Corp.41DInVitro International76B+Profile Solutions, Inc.——Rallybio Corporation47DUniversal Ibogaine Inc.——Advantis Corp.——Neighbors
Montgomery →Key facts
CEORam Mukunda
SectorHealthcare
IndustryBiotechnology
HeadquartersPotomac, MD
ExchangeAMEX: IGC
Employees70
IPO date2006-05-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.